Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib and Gemcitabine-Based Chemotherapy in Advanced Solid Tumors
NCT02227940Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceritinib in solid tumor and pancreatic cancer (PC) (3 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose and Recommended Phase II Dose. Started Jan 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
solid tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02227940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227940.